Supernus Pharmaceuticals | SUPN - Ebitda


Supernus Pharmaceuticals reported $29.23M in EBITDA for its fiscal quarter ending in March of 2026.





Ebitda Change Date
Abbott USD 3.27B 178M Dec/2025
ANI Pharmaceuticals USD 65.36M 5.76M Dec/2025
Aurora Cannabis CAD 18.48M 3.11M Dec/2025
Bristol-Myers Squibb USD 2.88B 1.36B Dec/2025
Canopy Growth CAD -2.87M 19.49M Dec/2025
Cara Therapeutics USD -2.39M 3.16M Mar/2025
Corcept Therapeutics USD 4.2M 6.5M Dec/2025
Eisai JPY -335M 30.43B Mar/2026
Eli Lilly USD 12.14B 4.26B Dec/2025
Novo Nordisk DKK 34.72B 2.57B Mar/2026
Pacira USD 40.24M 1.53M Mar/2026
Perrigo USD 141.6M 1.34B Mar/2026
Pfizer USD 5.99B 5.23B Mar/2026
Supernus Pharmaceuticals USD 29.23M 19.27M Mar/2026
United Therapeutics USD 379.5M 83.4M Dec/2025
Xeris Pharmaceuticals USD 25.09M 7.67M Dec/2025